<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-08244R2</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0005354</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Immunology/Innate Immunity</subject><subject>Dermatology/Psoriasis and Other Inflammatory Diseases</subject><subject>Dermatology/Skin and Systemic Disease</subject></subj-group></article-categories><title-group><article-title>Wnt5a Exhibits Layer-Specific Expression in Adult Skin, Is Upregulated in Psoriasis, and Synergizes with Type 1 Interferon</article-title><alt-title alt-title-type="running-head">Wnt5a in Psoriasis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Romanowska</surname><given-names>Malgorzata</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>Alan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kellock</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bray</surname><given-names>Susan E.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>McLean</surname><given-names>Kathleen</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Donandt</surname><given-names>Susanne</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Foerster</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Division of Experimental Medicine, University of Dundee, Dundee, Scotland, United Kingdom</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Tayside Tissue Bank, University of Dundee, Dundee, Scotland, United Kingdom</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Dermatology, University of Dundee, Dundee, Scotland, United Kingdom</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Charit&#x000e9; Medical University, Berlin, Germany</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Didier</surname><given-names>Elizabeth</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Tulane National Primate Research Center, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>j.foerster@dundee.ac.uk</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: MR SB JF. Performed the experiments: MR AE DK SB KM SD JF. Analyzed the data: MR AE SD JF.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>28</day><month>4</month><year>2009</year></pub-date><volume>4</volume><issue>4</issue><elocation-id>e5354</elocation-id><history><date date-type="received"><day>12</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>17</day><month>3</month><year>2009</year></date></history><copyright-statement>Romanowska et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p>Wnt5a is a member of the wingless-type patterning regulators important in pre-natal development. The expression and distribution of Wnt5a and its receptors frizzled (fzd) 3 and fzd 5 in adult human skin have not been comprehensively studied to date.</p></sec><sec><title>Methodology/Principal Findings</title><p>We here show that Wnt5a, fzd3, fzd5, as well as fzd6 are restricted to specific layers in normal epidermis, analogous to their zonal distribution in hair follicles, suggesting a role in adult skin differentiation. In line, Wnt5a and fzd5 are both overexpressed and re-distributed in the epidermis of psoriasis which involves disturbed keratinocyte differentiation. Functionally, Wnt5a lowers the concentration of IFN required to induce target genes, and increases the magnitude of IFN target gene induction, suggesting a molecular mechanism underlying IFN hypersensitivity in psoriasis. Finally, we identify nedd8 and the amyloid precursor APP, previously shown to be upregulated in psoriasis, as targets of synergistic IFN&#x003b1;/Wnt5a induction.</p></sec><sec><title>Conclusions/Significance</title><p>The present data (i) suggest that Wnt5a regulates epidermal differentiation even in adult skin and (ii) identify synergistic induction of type 1 IFN target genes as a novel mode of Wnt5a action. Targeting Wnt5a in the skin may reduce IFN hypersensitivity and be of therapeutical value.</p></sec></abstract><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Wnt proteins regulate diverse biological processes. Wnt5a represents the prototypical so-called non-canonical Wnt family members which signal not by inducing, or may even inhibit, the transcriptional activation of &#x003b2;-catenin. Apart from its complex role in development, Wnt5a is expressed in various adult tissues. Among its diverse biological activities, Wnt5a promotes proliferation in endothelial cells and glioblastoma cells <xref ref-type="bibr" rid="pone.0005354-Cheng1">&#x0005b;1&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005354-Yu1">&#x0005b;3&#x0005d;</xref>, as well as adhesion in fibroblasts and breast cancer cells <xref ref-type="bibr" rid="pone.0005354-Kawasaki1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005354-Safholm1">&#x0005b;5&#x0005d;</xref>. Most recently, evidence has accumulated for the involvement of Wnt5a in inflammatory responses and innate immunity. Thus, Wnt5a is induced by Toll-like receptors and elicits secretion of IL12 and TNF&#x003b1; in response to mycobacterial infection <xref ref-type="bibr" rid="pone.0005354-Blumenthal1">&#x0005b;6&#x0005d;</xref>. Furthermore, Wnt5a is drastically upregulated in macrophages by LPS and IFN&#x003b3; and induces the production of the pro-inflammatory cytokines IL1, IL6, and IL8 <xref ref-type="bibr" rid="pone.0005354-Pereira1">&#x0005b;7&#x0005d;</xref>. Wnt5a is also upregulated in synovial fibroblasts of inflammatory joints in rheumatoid arthritis where it induces IL6, IL8, and IL15 <xref ref-type="bibr" rid="pone.0005354-Sen1">&#x0005b;8&#x0005d;</xref>.</p><p>The signal transduction of Wnt5a appears to be context-dependent <xref ref-type="bibr" rid="pone.0005354-Mikels1">&#x0005b;9&#x0005d;</xref>. In all of the inflammatory responses cited above, as well as in endothelial cell activation, the active receptor appears to be Frizzled (Fzd) 5 <xref ref-type="bibr" rid="pone.0005354-Murphy1">&#x0005b;10&#x0005d;</xref>. However, signalling through Fzd3, and Ror2 have been described <xref ref-type="bibr" rid="pone.0005354-Kawasaki1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005354-Mikels1">&#x0005b;9&#x0005d;</xref>.</p><p>The epidermis represents a dynamic system of highly regulated keratinocyte stem-cell renewal, proliferation, differentiation, and migration. At the same time, the epidermis acts as first-line barrier in innate immunity and, as such, maintains complex communication with resident dendritic cells and sub-epidermal endothelial cells and fibroblasts. Although Wnt5a is expressed in all of these cell types and its role in the development of skin appendages including hair follicles <xref ref-type="bibr" rid="pone.0005354-Reddy1">&#x0005b;11&#x0005d;</xref> and mammary glands <xref ref-type="bibr" rid="pone.0005354-Roarty1">&#x0005b;12&#x0005d;</xref> has been examined, surprisingly little is known about the expression, distribution, and function of Wnt5a in post-natal human epidermis.</p><p>Psoriasis is a very common chronic inflammatory skin disease with a prevalence of 2&#x02013;4&#x00025; in Caucasian populations. In psoriasis, keratinocyte proliferation as well as differentiation are perturbed, leading to a grossly thickened epidermis with an altered composition of normal epidermal layers. Apart from keratinocyte turnover, psoriasis involves a hyperactive innate immune response. Thus, iatrogenic administration of type 1 IFN (IFN&#x003b1; or IFN&#x003b2;) elicits disease flares in susceptible individuals, as does endogenous IFN release in the course of viral disease <xref ref-type="bibr" rid="pone.0005354-Downs1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005354-Kowalzick1">&#x0005b;14&#x0005d;</xref>. Moreover, keratinocytes from psoriasis patients are hypersensitive to type 1 IFN <xref ref-type="bibr" rid="pone.0005354-Eriksen1">&#x0005b;15&#x0005d;</xref> and epidermal dendritic cells produce IFN&#x003b1; leading to massive upregulation of type 1 IFN target genes <xref ref-type="bibr" rid="pone.0005354-Romanowska1">&#x0005b;16&#x0005d;</xref>. Indeed, hypersensitivity towards type 1 IFN induced by deletion of the IFN repressor IRF2 is sufficient to cause a psoriasis-like skin disease in mice <xref ref-type="bibr" rid="pone.0005354-Hida1">&#x0005b;17&#x0005d;</xref>.</p><p>We and others have previously found Wnt5a to be upregulated on the mRNA level in psoriasis <xref ref-type="bibr" rid="pone.0005354-Romanowska1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005354-Reischl1">&#x0005b;18&#x0005d;</xref>. Here, we show that Wnt5a and its putative receptors are localized to specific compartments in normal skin and that Wnt5a is both highly upregulated and re-distributed in the hyperproliferative epidermis in psoriasis. Functionally, we show that Wnt5a sensitizes keratinocytes towards type 1 IFN. Finally, we identify nedd8 and APP as novel targets of synergistic IFN/Wnt5a activation.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Immunohistochemistry</title><p>Paraffin-embedded samples were obtained from the Tayside Tissue bank. Prior to biopsy, patients gave written consent to storage and analysis of biopsy samples. Storage and use of all tissues included in the work presented here was approved by the Tayside Committee on Medical Research Ethics B (REC ref. Nr. 07/S1402/90). Antibodies used were anti wnt5a (R&#x00026;D, order nr. AF645, final dilution 1&#x02236;400), anti-frizzled 3 (Insight Biotech, ordered through Acris Antibodies, Germany, order nr. SP4568P, 1&#x02236;200), anti-frizzled 5 (Cambridge Bioscience, ARP41245_P050, 1&#x02236;800), anti-frizzled 6 (GenWay, 18-461-10538, ordered through Acris Antibodies, Germany; 1&#x02236;400). A detailed protocol is given in <xref ref-type="supplementary-material" rid="pone.0005354.s001">Supporting Methods S1</xref>.</p></sec><sec id="s2b"><title>Keratinocyte primary culture and western blot</title><p>All studies on human samples were done with prior approval of the local institional ethics committee. Processing of biopsy samples and primary keratinocyte culture was performed as described <xref ref-type="bibr" rid="pone.0005354-Romanowska1">&#x0005b;16&#x0005d;</xref>. Cells were fractionated using the NE-PER kit (Pierce, order-nr 78833) and 20 &#x000b5;g of protein loaded per lane onto 15&#x00025; acrylamide-SDS gels. Blotting was performed on a semi-dry blotter onto nitro-cellulose membranes (Schleicher &#x00026; Schell, 10 402 594). Blots were blocked in Tris-buffered saline containing 0.1&#x00025; Tween-20 (TBST) and incubated with primary antibodies in TBST containing 4&#x00025; dry milk as follows: rabbit anti-human nedd8 (Cell Signaling, #2745) and rabbit anti-human Amyloid &#x003b2; precursor protein (Biozol, ab12269) at 1&#x02236;1000, respectively, overnight at 4&#x000b0;C. Secondary antibody was anti-rabbit-HRP (Amersham Biosciences, NA934) at 1&#x02236;2000 for 1 h at RT. Blots were developed with ECL Plus (Amersham #RPN2 132) and scanned with a CCD camera.</p></sec><sec id="s2c"><title>Stimulation with Wnt5a-mimic peptide and IFN&#x003b1;</title><p>Formylated hexapeptide formyl-MDGCEL <xref ref-type="bibr" rid="pone.0005354-Safholm1">&#x0005b;5&#x0005d;</xref> was synthesized by Pepscan Systems, reconstituted to 10 mM in PBS, aliquoted and stored at &#x02212;80&#x000b0;C. Primary keratinocytes at 50&#x00025; confluence were stimulated with 100 &#x000b5;M final concentration of Wnt5a-mimic peptide for 18 h. Stimulation with recombinant human IFN&#x003b1; (PBL Biomedical Labs, order-nr 3410) was carried out analogously with 20 ng/ml final concentration. For the concentration response, final concentrations were 3, 10, 30, 100 und 300 ng/ml, respectively.</p></sec><sec id="s2d"><title>Expression profiling</title><p>RNA was isolated and reverse transcribed to cDNA as described <xref ref-type="bibr" rid="pone.0005354-Romanowska1">&#x0005b;16&#x0005d;</xref>. cDNA was fluorescence-labelled, hybridized to SkinPatho microarrays (Miltenyi Biotech), and scanned by the in-house microarray facility of the Charit&#x000e9; Medical University, Berlin, Germany. Raw data were adjusted for red/green bias. Excel-based auto-filtering was used to exclude all transcripts lower than ten fluorescence units above the detection threshold in both the red- and green-labelled samples. P-values were determined using a standard t-test as indicated in the respective tables.</p></sec><sec id="s2e"><title>Wnt5a transfection</title><p>Full-length human wnt5a cDNA was purchased from Origene. Five&#x000d7;10<sup>5</sup> HaCat keratinocytes were cultivated in RPMI1640 medium and transfected in Advanced Medium (Gibco, order-nr 12491015) containing 2&#x00025; FCS with 40 &#x000b5;g Wnt5a-pCMV-XL4 or control vector (pCDNA6.1) using CaCl<sub>2</sub> precipitation as previously described for transfection of lentiviral vectors <xref ref-type="bibr" rid="pone.0005354-alYacoub1">&#x0005b;19&#x0005d;</xref>.</p></sec><sec id="s2f"><title>RT-PCR</title><p>RNA was extracted using the NucleoSpin II extraction kit (Machery-Nagel, #740 955) and cDNA prepared using SuperScript II RT, RnaseOut, Oligo(dT)<sub>12-18</sub> from Invitrogen. For PCR reactions, annealing temperature was uniformally 55&#x000b0;C. All genes were amplified for 25 cycles, except for wnt5a and IFI27 (30 cycles). Primers and conditions are detailed in <xref ref-type="supplementary-material" rid="pone.0005354.s001">Supporting Methods S1</xref>.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Dysregulation of Wnt-signalling in hyperproliferative epidermis</title><p>Psoriasis is a skin disease characterized by hyperproliferation, as well as aberrant differentiation of epidermal keratinocytes. In the course of extensive expression profiling we previously noted that the non-canonical Wnt family member Wnt5a was greatly upregulated in psoriatic epidermis <xref ref-type="bibr" rid="pone.0005354-Romanowska1">&#x0005b;16&#x0005d;</xref>. Accordingly, we carried out a more comprehensive expression analysis of Wnt-signalling molecules in psoriatic skin. As shown in <xref ref-type="table" rid="pone-0005354-t001">table 1</xref>, only Wnt5a and Fzd6 were significantly upregulated whereas the &#x003b2;-catenin inhibitor ICAT was downregulated (shown in bold print), in confirmation of previous findings <xref ref-type="bibr" rid="pone.0005354-Reischl1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005354-Haider1">&#x0005b;20&#x0005d;</xref>.</p><table-wrap id="pone-0005354-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005354.t001</object-id><label>Table 1</label><caption><title>Expression of Wnt-related genes in psoriasis.<xref ref-type="table-fn" rid="nt101">1</xref></title></caption><graphic id="pone-0005354-t001-1" xlink:href="pone.0005354.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005354-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Gene</td><td align="left" rowspan="1" colspan="1">Location</td><td align="left" rowspan="1" colspan="1">p-value</td><td align="left" rowspan="1" colspan="1">fold change</td></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1">Wnt proteins</td></tr><tr><td align="left" rowspan="1" colspan="1">WNT1</td><td align="left" rowspan="1" colspan="1">12q13</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" rowspan="1" colspan="1">WNT2</td><td align="left" rowspan="1" colspan="1">7q31</td><td align="left" rowspan="1" colspan="1">0.83</td><td align="left" rowspan="1" colspan="1">1.07</td></tr><tr><td align="left" rowspan="1" colspan="1">WNT2B</td><td align="left" rowspan="1" colspan="1">1p13</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" rowspan="1" colspan="1">WNT4</td><td align="left" rowspan="1" colspan="1">1p36.23-p35.1</td><td align="left" rowspan="1" colspan="1">0.78</td><td align="left" rowspan="1" colspan="1">&#x02212;1.06</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>WNT5A</bold></td><td align="left" rowspan="1" colspan="1">3p21-p14</td><td align="left" rowspan="1" colspan="1">0.0004</td><td align="left" rowspan="1" colspan="1">4.54</td></tr><tr><td align="left" rowspan="1" colspan="1">WNT6</td><td align="left" rowspan="1" colspan="1">2q35</td><td align="left" rowspan="1" colspan="1">0.017</td><td align="left" rowspan="1" colspan="1">1.79</td></tr><tr><td align="left" rowspan="1" colspan="1">WNT7A</td><td align="left" rowspan="1" colspan="1">3p25</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" rowspan="1" colspan="1">WNT8B</td><td align="left" rowspan="1" colspan="1">10q24</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" rowspan="1" colspan="1">WNT10B</td><td align="left" rowspan="1" colspan="1">12q13</td><td align="left" rowspan="1" colspan="1">0.24</td><td align="left" rowspan="1" colspan="1">&#x02212;1.37</td></tr><tr><td align="left" rowspan="1" colspan="1">WNT11</td><td align="left" rowspan="1" colspan="1">11q13.5</td><td align="left" rowspan="1" colspan="1">0.14</td><td align="left" rowspan="1" colspan="1">&#x02212;1.53</td></tr><tr><td colspan="4" align="left" rowspan="1">Frizzled-related proteins</td></tr><tr><td align="left" rowspan="1" colspan="1">FZD1</td><td align="left" rowspan="1" colspan="1">7q21</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">&#x02212;1.42</td></tr><tr><td align="left" rowspan="1" colspan="1">FZD2</td><td align="left" rowspan="1" colspan="1">17q21.1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" rowspan="1" colspan="1">FZD3</td><td align="left" rowspan="1" colspan="1">17q21.1</td><td align="left" rowspan="1" colspan="1">0.39</td><td align="left" rowspan="1" colspan="1">&#x02212;1.15</td></tr><tr><td align="left" rowspan="1" colspan="1">FZD4</td><td align="left" rowspan="1" colspan="1">11q14.2</td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1">1.15</td></tr><tr><td align="left" rowspan="1" colspan="1">FZD5</td><td align="left" rowspan="1" colspan="1">2q33-q34</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">1.34</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FZD6</bold></td><td align="left" rowspan="1" colspan="1">8q22.3-q23.1</td><td align="left" rowspan="1" colspan="1">0.027</td><td align="left" rowspan="1" colspan="1">1.99</td></tr><tr><td align="left" rowspan="1" colspan="1">FZD7</td><td align="left" rowspan="1" colspan="1">2q33</td><td align="left" rowspan="1" colspan="1">0.056</td><td align="left" rowspan="1" colspan="1">&#x02212;1.58</td></tr><tr><td align="left" rowspan="1" colspan="1">FZD9</td><td align="left" rowspan="1" colspan="1">7q11.23</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" rowspan="1" colspan="1">FRZB</td><td align="left" rowspan="1" colspan="1">2qter</td><td align="left" rowspan="1" colspan="1">0.45</td><td align="left" rowspan="1" colspan="1">&#x02212;1.41</td></tr><tr><td align="left" rowspan="1" colspan="1">SFRP1</td><td align="left" rowspan="1" colspan="1">8p12-p11.1</td><td align="left" rowspan="1" colspan="1">0.16</td><td align="left" rowspan="1" colspan="1">&#x02212;1.49</td></tr><tr><td align="left" rowspan="1" colspan="1">SFRP4</td><td align="left" rowspan="1" colspan="1">7p14.1</td><td align="left" rowspan="1" colspan="1">0.10</td><td align="left" rowspan="1" colspan="1">&#x02212;1.45</td></tr><tr><td colspan="4" align="left" rowspan="1">Other membrane receptors</td></tr><tr><td align="left" rowspan="1" colspan="1">LRP5</td><td align="left" rowspan="1" colspan="1">11q13.4</td><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">&#x02212;1.08</td></tr><tr><td align="left" rowspan="1" colspan="1">LRP6</td><td align="left" rowspan="1" colspan="1">12p11-p13</td><td align="left" rowspan="1" colspan="1">0.37</td><td align="left" rowspan="1" colspan="1">1.07</td></tr><tr><td align="left" rowspan="1" colspan="1">LRP1</td><td align="left" rowspan="1" colspan="1">12q13-q14</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">&#x02212;1.30</td></tr><tr><td align="left" rowspan="1" colspan="1">ROR2</td><td align="left" rowspan="1" colspan="1">9q22</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" rowspan="1" colspan="1">RYK</td><td align="left" rowspan="1" colspan="1">3q22</td><td align="left" rowspan="1" colspan="1">0.22</td><td align="left" rowspan="1" colspan="1">&#x02212;1.38</td></tr><tr><td colspan="4" align="left" rowspan="1">Wnt-inhibitors</td></tr><tr><td align="left" rowspan="1" colspan="1">WIF1</td><td align="left" rowspan="1" colspan="1">12q13.13</td><td align="left" rowspan="1" colspan="1">0.24</td><td align="left" rowspan="1" colspan="1">&#x02212;1.58</td></tr><tr><td align="left" rowspan="1" colspan="1">DKK1</td><td align="left" rowspan="1" colspan="1">10q11.2</td><td align="left" rowspan="1" colspan="1">0.39</td><td align="left" rowspan="1" colspan="1">&#x02212;1.47</td></tr><tr><td align="left" rowspan="1" colspan="1">DKK4</td><td align="left" rowspan="1" colspan="1">8p11.2-11.1</td><td align="left" rowspan="1" colspan="1">0.37</td><td align="left" rowspan="1" colspan="1">1.12</td></tr><tr><td colspan="4" align="left" rowspan="1">Downstream effectors</td></tr><tr><td align="left" rowspan="1" colspan="1">DVL3</td><td align="left" rowspan="1" colspan="1">3q27</td><td align="left" rowspan="1" colspan="1">0.99</td><td align="left" rowspan="1" colspan="1">&#x02212;1.01</td></tr><tr><td align="left" rowspan="1" colspan="1">GSK3B</td><td align="left" rowspan="1" colspan="1">3q13.3</td><td align="left" rowspan="1" colspan="1">0.09</td><td align="left" rowspan="1" colspan="1">1.26</td></tr><tr><td align="left" rowspan="1" colspan="1">APC</td><td align="left" rowspan="1" colspan="1">5q21-q22</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" rowspan="1" colspan="1">CTNNB1</td><td align="left" rowspan="1" colspan="1">3p21</td><td align="left" rowspan="1" colspan="1">0.95</td><td align="left" rowspan="1" colspan="1">1.02</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CTNNBIP1</bold></td><td align="left" rowspan="1" colspan="1">1p36.22</td><td align="left" rowspan="1" colspan="1">0.006</td><td align="left" rowspan="1" colspan="1">&#x02212;2.42</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label>1</label><p>Expression of wnt-signalling related molecules was analyzed using the Affymetrix U95A microarray. Data shown represent fold-changes in psoriatic lesional vs. non-lesional skin of n&#x0200a;&#x0003d;&#x0200a;5 independent donors, as detailed in <xref ref-type="bibr" rid="pone.0005354-Romanowska1">&#x0005b;16&#x0005d;</xref>. <bold>Bold</bold>-print: p&#x0003c;0.05 and fold-change &#x0003e;1.5; n.d.: not detected.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Expression of Wnt5a and Fzd receptors in adult human epidermis</title><p>Before analyzing Wnt5a expression in psoriasis on the protein level, we first performed a detailed immunohistochemical expression analysis in normal adult human skin which has not been published to date. We included Fzd3 and Fzd5 in this analysis, since these have been reported to bind Wnt5a, as well as Fzd6, as it was found upregulated in psoriasis (<xref ref-type="table" rid="pone-0005354-t001">table 1</xref>) and squamous cell carcinoma <xref ref-type="bibr" rid="pone.0005354-Reischl1">&#x0005b;18&#x0005d;</xref>. The epidermal expression profiles are shown in <xref ref-type="fig" rid="pone-0005354-g001">figure 1</xref>. Wnt5a is mainly expressed in the basal layer and few cells in the upper spinous and granular layers. Fzd3 was found to be strictly confined to the spinous layer in the epidermis and was the only receptor exhibiting a non-homogeneous patchy expression pattern such that strongly positive cells are intersperced with Fzd3-negative cells in a mosaic-like pattern. Fzd5 expression is strictly limited to the granular layer (magnified inset) whereas Fzd6, similar to Wnt5a, is mainly found in the basal layer, corresponding to its distribution in murine skin <xref ref-type="bibr" rid="pone.0005354-Guo1">&#x0005b;21&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0005354-g001">fig. 1e</xref> therein). In the hair follicle, Fzd 3 is mainly expressed in the inner root sheath, Fzd 5 in the precortex, and Wnt5a in the papilla (<xref ref-type="fig" rid="pone-0005354-g002">fig. 2</xref>). These findings are consistent with previous data obtained in postnatal murine skin <xref ref-type="bibr" rid="pone.0005354-Reddy1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005354-Hung1">&#x0005b;22&#x0005d;</xref>, thereby also confirming the specificity of the antibodies employed here. In addition, we also observe Fzd6 expression in the cortex. Taken together, the highly compartmentalized distribution of Wnt5a and Fzd isoforms in adult human epidermis is reminiscent of their zonal restriction in hair follicles (see <xref ref-type="fig" rid="pone-0005354-g002">fig. 2</xref>, lower right), strongly suggesting that Wnt signalling regulates differentiation not only in hair follicles, but also in the epidermis.</p><fig id="pone-0005354-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005354.g001</object-id><label>Figure 1</label><caption><title>Expression of Wnt5a, Fzd3, Fzd5, and Fzd6 in adult human epidermis.</title><p>Immunohistochemistry of paraffin-embedded skin samples was performed as detailed in <xref ref-type="sec" rid="s2">Methods</xref>. Panels shown are at 200&#x000d7; magnification.</p></caption><graphic xlink:href="pone.0005354.g001"/></fig><fig id="pone-0005354-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005354.g002</object-id><label>Figure 2</label><caption><title>Expression of Wnt5a and Fzd3, Fzd5, and Fzd6 in adult human hair follicles.</title><p>Immunohistochemistry of paraffin-embedded skin samples was performed as detailed in <xref ref-type="sec" rid="s2">Methods</xref>. Panels shown are at 200&#x000d7; magnification. The hair follicle schematic for the cartoon on lower right was adapted from <xref ref-type="bibr" rid="pone.0005354-Reddy1">&#x0005b;11&#x0005d;</xref>.</p></caption><graphic xlink:href="pone.0005354.g002"/></fig></sec><sec id="s3c"><title>Expression of Wnt5a and receptors in psoriasis</title><p>We next characterized the expression of Wnt5a, Fzd3, Fzd5, Fzd6 in psoriasis lesions which are characterized by hyperproliferation and dysregulated differentiation. As shown in <xref ref-type="fig" rid="pone-0005354-g003">figure 3</xref>, Wnt5a was found to be overexpressed throughout the entire spinous layer. Moreover, as shown in the top panel on the right, activated endothelials cells and dermal fibroblasts are strongly positive for Wnt5a. Finally, the neutrophil aggregates in the stratum corneum, a hallmark of psoriasis, also express Wnt5a (arrow, top left panel). While Fzd3 shows an expression pattern qualitatively unchanged to normal epidermis, Fzd5 is shifted from its exclusive expression in the granular layer towards overexpression in all epidermal layers as well as expression in the dermal endothelia (high power image on right). Fzd6 is also heavily overexpressed as well as in the endothelia but retains the same relative expression level as in normal epidermis (strongest staining in the basal layer). Taken together, Wnt5a, Fzd5, and Fzd6 are strongly upregulated in psoriasis. In addition, Wnt5a and Fzd5 exhibit an altered qualitative distribution.</p><fig id="pone-0005354-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005354.g003</object-id><label>Figure 3</label><caption><title>Expression of Wnt5a and Fzd proteins in psoriasis.</title><p>(a) Immunohistochemistry of Wnt5a was performed as detailed in <xref ref-type="sec" rid="s2">Methods</xref>. Panels on left are 200&#x000d7;, panels on right are at 400&#x000d7; magnification. Wnt5a staining was virtually identical in n&#x0200a;&#x0003d;&#x0200a;12 samples from independent patients.</p></caption><graphic xlink:href="pone.0005354.g003"/></fig></sec><sec id="s3d"><title>Overexpression of Wnt5a in keratinocytes from psoriasis patients in vitro</title><p>We next sought to clarify whether any of the observed changes represent a cell-autonomous feature of the hyperproliferative keratincoytes in psoriasis patients, i.e. whether they can be detected in vitro in the absence of the inflammatory micro-environment. To this end, we expanded keratinocytes from <italic>non</italic>-lesional skin of psoriasis patients, or healthy control patients, <italic>in vitro</italic> and performed microarray-based expression profliling. As shown in <xref ref-type="table" rid="pone-0005354-t002">table 2</xref>, Wnt5a was found significantly upregulated on the mRNA level in keratinocytes derived from psoriasis patients. This was not the case for Fzd3 and Fzd5 (Fzd6 was not represented on the Skin-Patho microarray used for this experiment). By western blot, we were able to confirm that Wnt5a protein is indeed overexpressed in primary human keratinocytes expanded from non-lesional skin of psoriasis patients (<xref ref-type="fig" rid="pone-0005354-g004">fig. 4</xref>). Although the low sample number precludes a definite statement, these data suggest that upregulation of Wnt5a may constitute of cell-autonomous feature of psoriatic keratinocytes. Regardless of this notion, the clear difference in Wnt5a expression between the psoriasis- and control-derived keratinocytes characterized here is suitable to study effects of endogenous Wnt5a overexpression (see below).</p><fig id="pone-0005354-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005354.g004</object-id><label>Figure 4</label><caption><title>Overexpression of Wnt5a in psoriatic keratinocytes in vitro.</title><p>Keratinocytes from non-affected skin from psoriasis patients or healthy control skin were expanded in vitro for 14 days, fractionated in nuclear (n) or cytoplasmic/membrane fractions (c/m), and subjected to western blot, as detailed in <xref ref-type="sec" rid="s2">Methods</xref>. 50 &#x000b5;g of protein were loaded per lane. The bottom panel shows the Poinceau-S stain of the blot verifying even protein loading. &#x0002a;&#x0200a;&#x0003d;&#x0200a;non-specific band also visible in the Poinceau S stain.</p></caption><graphic xlink:href="pone.0005354.g004"/></fig><table-wrap id="pone-0005354-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005354.t002</object-id><label>Table 2</label><caption><title>Genes with altered expression in cultured psoriatic keratinocytes.<xref ref-type="table-fn" rid="nt102">1</xref></title></caption><graphic id="pone-0005354-t002-2" xlink:href="pone.0005354.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005354-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">FC in vitro<xref ref-type="table-fn" rid="nt103">2</xref></td><td align="left" rowspan="1" colspan="1">p-value<xref ref-type="table-fn" rid="nt104">3</xref></td><td align="left" rowspan="1" colspan="1">FC skin<xref ref-type="table-fn" rid="nt105">4</xref></td><td align="left" rowspan="1" colspan="1">p-value skin<xref ref-type="table-fn" rid="nt105">4</xref></td></tr></thead><tbody><tr><td colspan="5" align="left" rowspan="1">Increased expression</td></tr><tr><td align="left" rowspan="1" colspan="1">KYNURENINASE</td><td align="left" rowspan="1" colspan="1">5.5</td><td align="left" rowspan="1" colspan="1">0.003</td><td align="left" rowspan="1" colspan="1">3.4</td><td align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">COL3A1</td><td align="left" rowspan="1" colspan="1">3.2</td><td align="left" rowspan="1" colspan="1">0.006</td><td align="left" rowspan="1" colspan="1">2.9</td><td align="left" rowspan="1" colspan="1">0.018</td></tr><tr><td align="left" rowspan="1" colspan="1">COL5A2</td><td align="left" rowspan="1" colspan="1">3.1</td><td align="left" rowspan="1" colspan="1">0.006</td><td align="left" rowspan="1" colspan="1">n.s.</td><td align="left" rowspan="1" colspan="1">n.s.</td></tr><tr><td align="left" rowspan="1" colspan="1">COL6A1</td><td align="left" rowspan="1" colspan="1">3.0</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">n.s.</td><td align="left" rowspan="1" colspan="1">n.s.</td></tr><tr><td align="left" rowspan="1" colspan="1">WNT5A</td><td align="left" rowspan="1" colspan="1">2.9</td><td align="left" rowspan="1" colspan="1">0.003</td><td align="left" rowspan="1" colspan="1">4.5</td><td align="left" rowspan="1" colspan="1">0.0004</td></tr><tr><td align="left" rowspan="1" colspan="1">COL1A1</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">0.009</td><td align="left" rowspan="1" colspan="1">n.s.</td><td align="left" rowspan="1" colspan="1">n.s.</td></tr><tr><td align="left" rowspan="1" colspan="1">CXCL1 (GRO1)</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">0.008</td><td align="left" rowspan="1" colspan="1">n.s.</td><td align="left" rowspan="1" colspan="1">n.t.</td></tr><tr><td align="left" rowspan="1" colspan="1">MMP2</td><td align="left" rowspan="1" colspan="1">1.8</td><td align="left" rowspan="1" colspan="1">0.008</td><td align="left" rowspan="1" colspan="1">n.s.</td><td align="left" rowspan="1" colspan="1">n.s.</td></tr><tr><td colspan="5" align="left" rowspan="1">Decreased expression</td></tr><tr><td align="left" rowspan="1" colspan="1">ARHE (Rho8)</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">0.002</td><td align="left" rowspan="1" colspan="1">3.3</td><td align="left" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">PLK2 (SNK)</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">0.010</td><td align="left" rowspan="1" colspan="1">2.4</td><td align="left" rowspan="1" colspan="1">0.002</td></tr></tbody></table><table-wrap-foot><fn id="nt102"><label>1</label><p>Keratinocytes from non-lesional skin of psoriasis patients (n&#x0200a;&#x0003d;&#x0200a;3) or normal control skin (n&#x0200a;&#x0003d;&#x0200a;4) were expanded in vitro and cultured for appr. 14 days, followed by expression profiling using the PIQUOR Skin-Patho microarray, as detailed in <xref ref-type="sec" rid="s2">methods</xref>.</p></fn><fn id="nt103"><label>2</label><p>Fold change (relative expression levels in keratinocytes from psoriasis patients vs. controls).</p></fn><fn id="nt104"><label>3</label><p>Statistical significance, as determined by a non-paired two sided t-test.</p></fn><fn id="nt105"><label>4</label><p>Overexpression in lesional vs. non-lesional psoriatic skin, as previously reported <xref ref-type="bibr" rid="pone.0005354-Romanowska1">&#x0005b;16&#x0005d;</xref>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3e"><title>Wnt5a induces type I interferon target genes</title><p>In order to screen for cellular signalling pathways possibly affected by Wnt5a in keratinocytes, we stimulated keratinocytes in vitro with a formylated wnt5a-derived hexapeptide shown to mimic the effect of full-length wnt5a on adherence and motility in vivo and in vitro <xref ref-type="bibr" rid="pone.0005354-Safholm1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005354-Safholm2">&#x0005b;23&#x0005d;</xref> and compared global gene expression between keratinocytes stimulated with Wnt5a-mimic peptide and control peptide. We performed this experiment both with keratinocytes from psoriasis patients and from control patients. Since there were no significant differences in the effect of the Wnt5a-mimic peptide on keratinocytes from psoriasis patients and controls (not shown), both groups were analyzed together. Of the 1133 transcripts represented on the Piquor SkinPatho microarray, only four exhibited a greater than 1.2-fold change: nedd8, MX1 (IFI-78), IFI-27, and APP (<xref ref-type="table" rid="pone-0005354-t003">table 3</xref>). Both MX1 and IFI-27 are type 1 interferon target genes previously also found to be upregulated in psoriatic skin lesions <xref ref-type="bibr" rid="pone.0005354-Romanowska1">&#x0005b;16&#x0005d;</xref>. Induction of all four target genes could subsequently be verified by RT-PCR of HaCat keratinocytes transfected either with full-length Wnt5a cDNA or control vector (<xref ref-type="fig" rid="pone-0005354-g005">fig. 5a</xref>). Importantly, type 1 IFN genes themselves (&#x003b1; or &#x003b2;) were not induced by Wnt5a (not shown).</p><fig id="pone-0005354-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005354.g005</object-id><label>Figure 5</label><caption><title>Wnt5a induces type 1 IFN target genes and causes IFN hypersensitivity.</title><p>(a) HaCat keratinocytes were transfected with full length Wnt5a cDNA or control vector (pCDNA6.1). 12 h after transfection, the expression of nedd8, MX1, IFI-27, and APP was determined by RT-PCR, as described in <xref ref-type="sec" rid="s2">Methods</xref>. The expression of Wnt5a was also determined to verify overexpression. (b) HaCat keratinocytes transfected with full-length Wnt5a cDNA (open symbols) or control vector (closed symbols) and stimulated with the indicated concentrations of IFN&#x003b1; for 18 h. The expression of IFI27 was then assessed using RT-PCR and quantified densitometrically. The data shown represent mean&#x000b1;s.d. of two independent experiments. (c) Keratinocytes from non-lesional psoriatic skin with elevated endogenous Wnt5a levels or from healthy control skin were expanded in vitro for 14 days and stimulated for 18 h with 20 ng/ml IFN&#x003b1;. Global gene expression was determined using the piquor skin-patho microarray. Plotted are the &#x02013;fold change (IFN&#x003b1; vs. basal expression) of all genes (41 of 1133) exhibiting a &#x02265;2-fold induction by IFN&#x003b1;. The mean fold-changes of cells from n&#x0200a;&#x0003d;&#x0200a;3 controls are plotted along the x-axis, the mean fold-change of cells from n&#x0200a;&#x0003d;&#x0200a;4 cells are plotted along the y-axis. Dots represent mean values, horizontal lines represent s.d. among the controls, vertical lines represent s.d. among cells from psoriasis patients. The dashed line marks the theoretical equal magnitude of gene induction.</p></caption><graphic xlink:href="pone.0005354.g005"/></fig><table-wrap id="pone-0005354-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005354.t003</object-id><label>Table 3</label><caption><title>Genes induced in keratinocytes by Wnt5a in vitro.<xref ref-type="table-fn" rid="nt106">1</xref></title></caption><graphic id="pone-0005354-t003-3" xlink:href="pone.0005354.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005354-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Gene ID</td><td colspan="3" align="left" rowspan="1">fold change</td><td align="left" rowspan="1" colspan="1">p-value<xref ref-type="table-fn" rid="nt107">2</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Psoriasis</td><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NEDD8</td><td align="left" rowspan="1" colspan="1">1.34</td><td align="left" rowspan="1" colspan="1">1.35</td><td align="left" rowspan="1" colspan="1">1.35</td><td align="left" rowspan="1" colspan="1">2&#x000d7;10<sup>&#x02212;7</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">IFI-78 (MX1)</td><td align="left" rowspan="1" colspan="1">1.53</td><td align="left" rowspan="1" colspan="1">1.16</td><td align="left" rowspan="1" colspan="1">1.35</td><td align="left" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">IFI27</td><td align="left" rowspan="1" colspan="1">1.52</td><td align="left" rowspan="1" colspan="1">1.12</td><td align="left" rowspan="1" colspan="1">1.32</td><td align="left" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">APP</td><td align="left" rowspan="1" colspan="1">1.41</td><td align="left" rowspan="1" colspan="1">1.14</td><td align="left" rowspan="1" colspan="1">1.28</td><td align="left" rowspan="1" colspan="1">0.002</td></tr></tbody></table><table-wrap-foot><fn id="nt106"><label>1</label><p>Primary keratinocytes expanded from healthy control donors (n&#x0200a;&#x0003d;&#x0200a;3) or psoriasis patients (n&#x0200a;&#x0003d;&#x0200a;3) were cultivated in the presence or absence of Wnt5a mimic peptide <xref ref-type="bibr" rid="pone.0005354-Safholm1">&#x0005b;5&#x0005d;</xref> or control peptide for 48 h and gene expression subsequently analyzed as detailed in <xref ref-type="sec" rid="s2">Methods</xref>. Total fold-changes shown represent the average across all six samples (wnt5a vs. control peptide).</p></fn><fn id="nt107"><label>2</label><p>As determined by a two-sided paired t-test.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3f"><title>Wnt5a causes hypersensitivity toward type 1 interferon</title><p>Since the magnitude of mRNA upregulation was rather modest for an IFN target gene, we hypothesized that a possible function of Wnt5a might be to &#x0201e;prime&#x0201c; cells for synergistic induction by type 1 IFN. To test this hypothesis, we transfected HaCat keratinocytes either with full-length Wnt5a cDNA or control vector. Transfected cells were then exposed to increasing concentrations of IFN&#x003b1; and expression of the IFN&#x003b1; target gene MX1 determined by PCR. As shown in <xref ref-type="fig" rid="pone-0005354-g005">figure 5b</xref>, concurrent overexpression of Wnt5a caused a left shift in the concentration response curve to all IFN&#x003b1; where the calculated apparent EC-50 shifted from 22 ng/ml to 6 ng/ml, suggesting that overexpression of Wnt5a indeed increases sensitivity toward IFN&#x003b1;. This observation predicts that low concentrations of IFN&#x003b1; should cause a greater magnitude of IFN target gene induction in cells with increased Wnt5a expression. To test this, we compared the response to type 1 IFN between primary epidermal keratinocytes from psoriasis patients harbouring increased endogenous Wnt5a protein levels (see above, <xref ref-type="fig" rid="pone-0005354-g004">fig. 4</xref>) to keratinocytes from control probands. We stimulated these cells with 20 ng/ml of IFN&#x003b1;, a concentration which, according to the data presented above, would be expected to cause a higher magnitude of IFN&#x003b1; target gene induction in keratinocytes with endogenous Wnt5a overexpression. After 18 h of stimulation, global gene expression was analyzed using the Piquor SkinPatho microarray. <xref ref-type="fig" rid="pone-0005354-g005">Figure 5c</xref> shows all transcripts (41 of 1133) present on the array which were induced at least a two-fold by IFN&#x003b1;. The induction level is expressed as mean fold-change of all control keratinocytes (n&#x0200a;&#x0003d;&#x0200a;4, along the x-axis) vs. mean fold-change of all psoriasis keratinocytes (n&#x0200a;&#x0003d;&#x0200a;3, along the y-axis). Strikingly, all 41 IFN-responsive target genes are induced to a higher level in the keratinocytes harbouring higher Wnt5a levels, corresponding to a statistically highly significant 1.8&#x000b1;1.1-fold relative hyper-induction across all target genes (p&#x0200a;&#x0003d;&#x0200a;0.001). These data confirm that hypersensitivity toward IFN&#x003b1;, i.e. increased IFN target gene induction at low IFN concentrations, is a general feature detectable for all target genes in primary cells with endogenous Wnt5a upregulation.</p></sec><sec id="s3g"><title>APP and nedd8 are synergistically induced by type 1 IFN and Wnt5a</title><p>Apart from MX1 and IFI-27, the only transcripts induced by Wnt5a in keratinocytes were APP and nedd8 (see above, <xref ref-type="table" rid="pone-0005354-t003">table 3</xref> and <xref ref-type="fig" rid="pone-0005354-g005">figure 5</xref>). Wnt5a alone showed only a modest induction of both genes in keratinocytes. Likewise, stimulation by IFN&#x003b1; alone only caused a slight upregulation of either gene (1.4&#x000b1;0.6 fold and 1.6&#x000b1;0.4 fold for APP and nedd8, respectively). Therefore, we hypothesized that these genes, too, might be subject to synergistic induction by Wnt5a and type 1 IFN. To test this hypothesis we transfected HaCat keratinocytes either with control vector or full-length Wnt5a, and cultivated the transfected cells either in the presence or absence of 20 ng/ml IFN&#x003b1;. As shown in <xref ref-type="fig" rid="pone-0005354-g006">fig. 6a</xref>, a specific band at appr. 70 kd, corresponding to soluble APP, was induced upon either Wnt5a or IFN&#x003b1; stimulation, but more strongly upon co-stimulation with both factors. Synergistic induction of soluble APP is also evident upon densitometric quantification of the blot, as shown on the bottom of the figure. Nedd8 is a ubiquitin-like peptide covalently linked to a number of target proteins. In nuclear extracts of HaCat cells, a nedd8-reactive protein migrating at appr. 50 kd was present in control cells, but more abundant after either Wnt5a-transfection or IFN&#x003b1; stimulation and clearly synergistically induced by both factors (<xref ref-type="fig" rid="pone-0005354-g006">fig. 6b</xref>), which is also seen upon densitometric quantification. In conjunction with the transcriptional induction of nedd8 by IFN&#x003b1; as well as Wnt5a seen on the mRNA level (<xref ref-type="fig" rid="pone-0005354-g004">figure 4a</xref>), these data strongly suggest that nedd8 is synergistically induced by Wnt5a and IFN&#x003b1;. Taken together, APP (previously implicated in psoriasis pathogenesis) and nedd8 represent novel interferon targets induced significantly by the concurrent action of Wnt5a and IFN&#x003b1;.</p><fig id="pone-0005354-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005354.g006</object-id><label>Figure 6</label><caption><title>Synergistic induction of APP and nedd8 by Wnt5a and IFN&#x003b1;.</title><p>(a) HaCat cells were transfected either with control vector or Wnt5a, followed by incubation in the absence or presence of 20 ng/ml IFN&#x003b1; for 18 h. Whole cell lysates were subjected to SDS-PAGE and blotted with anti-APP. The visible band migrating at appr. 70 kd is consistent with &#x003b2;-secretase-cleaved sAPP. Poinceau-S stain of the membrane is shown as loading control. (b) HaCat cells were transfected and stimulated with IFN&#x003b1; as in (a), followed by preparation of nuclear extracts, SDS-PAGE, and western blot using anti-nedd8.</p></caption><graphic xlink:href="pone.0005354.g006"/></fig></sec></sec><sec id="s4"><title>Discussion</title><p>We here show that Wnt5a and its putative receptor Fzd5 are overexpressed in psoriasis, that Wnt5a increases the sensitivity of keratinocytes towards type 1 interferon, and that nedd8 and APP are synergistically induced by Wnt5a and IFN&#x003b1;.</p><p>The unexpected finding that Wnt5a and fzd3, fzd5, and fzd6 proteins are highly compartmentalized in normal adult human epidermis, reminiscent of the distribution of wnt signalling components in the hair follicle, raises the question of the role of this system in the dynamics of keratinocyte turnover in the skin. Of all relevant classical knock-out phenotypes, only Fzd6-deficient mice survive post term with intact epidermis except for abnormal hair whorls <xref ref-type="bibr" rid="pone.0005354-Guo1">&#x0005b;21&#x0005d;</xref>, suggesting that its physiological presence in the basal layer is dispensable. Therefore, inducible loss- or gain-of-function approaches will be required to delineate the functional role of wnt signalling in post-natal skin.</p><p>The marked overexpression of Wnt5a and Fzd5 in psoriasis suggest that this ligand-receptor pair may actively drive the chronic inflammatory and hyperproliferative nature of this phenotype. This idea receives further support from a large body of circumstantial evidence. First, WNT5a induces IL12 <xref ref-type="bibr" rid="pone.0005354-Blumenthal1">&#x0005b;6&#x0005d;</xref>, which is central to psoriasis, as indicated by the therapeutic efficacy of antibodies targeted at IL12p40 and by the genetic association of IL12 with psoriasis <xref ref-type="bibr" rid="pone.0005354-Cargill1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005354-Krueger1">&#x0005b;25&#x0005d;</xref>. Second, Wnt5a is itself strongly induced by STAT3 <xref ref-type="bibr" rid="pone.0005354-Katoh1">&#x0005b;26&#x0005d;</xref>, thereby acting as a potential effector molecule for the psoriasis-like skin disease seen in STAT3-overexpressing transgenic mice <xref ref-type="bibr" rid="pone.0005354-Sano1">&#x0005b;27&#x0005d;</xref>. Third, WNT5a induces epithelial differentiation and stimulates endothelial cell proliferation, both important elements of psoriasis. Fourth, Wnt5a is upregulated in wound healing <xref ref-type="bibr" rid="pone.0005354-Fathke1">&#x0005b;28&#x0005d;</xref> and psoriasis lesions can classically be triggered by skin wounding. Fifth, our data show that dermal fibroblasts in psoriasis are strongly positive for Wnt5a and activated fibroblasts from rheumatoid arthritis are synthesize inflammatory cytokines, most notably IL15, subsequent to Wnt5a/Fzd5 signalling <xref ref-type="bibr" rid="pone.0005354-Sen2">&#x0005b;29&#x0005d;</xref>. Sixth, Wnt5a derived from endothelia signals through Fzd5 to induce the translocation of NFAT and subsequent induction of IL-2 in T cells <xref ref-type="bibr" rid="pone.0005354-Murphy1">&#x0005b;10&#x0005d;</xref>. This effect may be highly relevant, since (i) continued T cell activation also represents a central element in psoriasis <xref ref-type="bibr" rid="pone.0005354-Boyman1">&#x0005b;30&#x0005d;</xref>, and (ii) Wnt5a-mediated T cell activation can be elicited by lithium which is one of the most potent clinical triggers of psoriasis flares <xref ref-type="bibr" rid="pone.0005354-Wolf1">&#x0005b;31&#x0005d;</xref>. Finally, and most importantly, WNT5a induces IFN hypersensitivity (see below), a central hallmark of psoriasis.</p><p>The relationship between Wnt5a and &#x003b2;-catenin signalling in psoriasis as well as physiological epidermal turn-over is unclear. Supra-basal accumulation of nuclear &#x003b2;-catenin in psoriasis has been reported <xref ref-type="bibr" rid="pone.0005354-Hampton1">&#x0005b;32&#x0005d;</xref>. Moreover, we here report down-regulation of two inhibitors of canonical wnt-signalling in psoriasis, ICAT (CTNNBIP1) and WIF (<xref ref-type="table" rid="pone-0005354-t001">table 1</xref>). Furthermore, the psoriasis-inducing effect of lithium mentioned above may also involve GSK&#x003b2;-inhibition and &#x003b2;-catenin activation in vivo. Thus, Wnt5a and &#x003b2;-catenin activation may occur concurrently in psoriasis. Indeed, retroviral overexpression of Wnt5a after wounding in mice did not antagonize nuclear translocation of &#x003b2;-catenin <xref ref-type="bibr" rid="pone.0005354-Fathke1">&#x0005b;28&#x0005d;</xref>.</p><p>Wnt5a signalling in psoriasis may also be related to the activation of the nuclear hormone receptor PPAR&#x003b4; which we have previously identified as a central mediator in psoriasis. Thus, Wnt5a may synergize with IFN&#x003b1; to induce the expression of PPAR&#x003b4; in activated T lymphocytes <xref ref-type="bibr" rid="pone.0005354-Sen2">&#x0005b;29&#x0005d;</xref>. Moreover, PPAR&#x003b4; stimulates keratinocyte proliferation and in several biological processes acts by antagonizing another PPAR isoform, PPAR&#x003b3; <xref ref-type="bibr" rid="pone.0005354-Romanowska1">&#x0005b;16&#x0005d;</xref>. Wnt5a also represses PPAR&#x003b3; transactivation thereby synergizing with PPAR&#x003b4; functionally <xref ref-type="bibr" rid="pone.0005354-Takada1">&#x0005b;33&#x0005d;</xref>. Conversally, PPAR&#x003b3; inhibits STAT3 <xref ref-type="bibr" rid="pone.0005354-Wang1">&#x0005b;34&#x0005d;</xref> which, when overexpressed, induces Wnt5a and causes a psoriasis-like phenotype in vivo <xref ref-type="bibr" rid="pone.0005354-Sano1">&#x0005b;27&#x0005d;</xref>.</p><p>The molecular mechanism of Wnt5a/IFN&#x003b1; crosstalk is elusive as no data exist on the effect of frizzled-mediated signalling on downstream effectors of IFN signalling. Our results do suggest that Fzd5 may be the responsible molecule at the receptor level and antibody-mediated neutralization studies will be able to clarify this issue. Moreoever, our data do not show a direct transcriptional upregulation of IFN genes or IFN receptors (data not shown) by Wnt5a activation. Down-stream of the membrane receptor, it is less clear at which point Fzd-mediated signals interact with IFN signalling relayers <xref ref-type="bibr" rid="pone.0005354-Platanias1">&#x0005b;35&#x0005d;</xref>. The present data should certainly prompt a more detailed analyses of the effect of Wnt5a on nuclear translocation and phosphorylation of factor involved in IFN signal transduction.</p><p>We here identify the APP amyloid precursor protein and the ubiquitin-like molecule nedd8 as bona fide targets of synergistic IFN&#x003b1;/Wnt5a induction. APP is upregulated and re-distributed in psoriasis lesions strikingly similar to Wnt5a and APP stimulates both proliferation and mobility of keratinocytes <xref ref-type="bibr" rid="pone.0005354-Siemes1">&#x0005b;36&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005354-Herzog1">&#x0005b;37&#x0005d;</xref>. Furthermore, processed amyloid &#x003b2; induces transcription of kynureninase, which we found to be strongly upregulated in psoriasis in vivo, as well as in psoriasis-derived cells in vitro (<xref ref-type="table" rid="pone-0005354-t002">table 2</xref>), and which can elicit an inflammatory skin reaction in vivo <xref ref-type="bibr" rid="pone.0005354-Ito1">&#x0005b;38&#x0005d;</xref>. Therefore, the induction of APP by Wnt5a/IFN may contribute to increased keratinocyte turnover and migration in psoriasis. As for nedd8, further studies must clarify which target proteins are neddylated by concurrent Wnt5a/IFN stimulation and whether these are involved in epidermal dynamics. However, the results presented here clearly show that, in addition to established IFN target genes, another class of targets exists which are synergistically induced by Wnt5a/IFN&#x003b1;. Thus, screening for such targets in other cell types such as T cells, endothelial cells, or fibroblasts, would delineate the profile of innate immune activation elicited by Wnt5a.</p><p>In conclusion, we here demonstrate compartmentalized distribution of Wnt-signalling components in adult skin, up-regulation of Wnt5a in hyperproliferative and differentiation-deficient epidermis, and identify sensitization for interferon as a novel function of Wnt signalling.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0005354.s001"><label>Supporting Methods S1</label><caption><p>(0.06 MB DOC)</p></caption><media xlink:href="pone.0005354.s001.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors with to acknowledge the excellent technical support of Dr. Ute Ungeth&#x000fc;m of the Charit&#x000e9; Medical University in-house microarray facility.</p></ack><ref-list><title>References</title><ref id="pone.0005354-Cheng1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>CW</given-names></name><name><surname>Yeh</surname><given-names>JC</given-names></name><name><surname>Fan</surname><given-names>TP</given-names></name><name><surname>Smith</surname><given-names>SK</given-names></name><name><surname>Charnock-Jones</surname><given-names>DS</given-names></name></person-group><year>2008</year><article-title>Wnt5a-mediated non-canonical Wnt signalling regulates human endothelial cell proliferation and migration.</article-title><source>Biochem Biophys Res Commun</source><volume>365</volume><fpage>285</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">17986384</pub-id></citation></ref><ref id="pone.0005354-Masckauchan1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Masckauchan</surname><given-names>TN</given-names></name><name><surname>Agalliu</surname><given-names>D</given-names></name><name><surname>Vorontchikhina</surname><given-names>M</given-names></name><name><surname>Ahn</surname><given-names>A</given-names></name><name><surname>Parmalee</surname><given-names>NL</given-names></name><etal/></person-group><year>2006</year><article-title>Wnt5a signaling induces proliferation and survival of endothelial cells in vitro and expression of MMP-1 and Tie-2.</article-title><source>Mol Biol Cell</source><volume>17</volume><fpage>5163</fpage><lpage>5172</lpage><pub-id pub-id-type="pmid">17035633</pub-id></citation></ref><ref id="pone.0005354-Yu1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>JM</given-names></name><name><surname>Jun</surname><given-names>ES</given-names></name><name><surname>Jung</surname><given-names>JS</given-names></name><name><surname>Suh</surname><given-names>SY</given-names></name><name><surname>Han</surname><given-names>JY</given-names></name><etal/></person-group><year>2007</year><article-title>Role of Wnt5a in the proliferation of human glioblastoma cells.</article-title><source>Cancer Lett</source></citation></ref><ref id="pone.0005354-Kawasaki1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>A</given-names></name><name><surname>Torii</surname><given-names>K</given-names></name><name><surname>Yamashita</surname><given-names>Y</given-names></name><name><surname>Nishizawa</surname><given-names>K</given-names></name><name><surname>Kanekura</surname><given-names>K</given-names></name><etal/></person-group><year>2007</year><article-title>Wnt5a promotes adhesion of human dermal fibroblasts by triggering a phosphatidylinositol-3 kinase/Akt signal.</article-title><source>Cell Signal</source></citation></ref><ref id="pone.0005354-Safholm1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Safholm</surname><given-names>A</given-names></name><name><surname>Leandersson</surname><given-names>K</given-names></name><name><surname>Dejmek</surname><given-names>J</given-names></name><name><surname>Nielsen</surname><given-names>CK</given-names></name><name><surname>Villoutreix</surname><given-names>BO</given-names></name><etal/></person-group><year>2006</year><article-title>A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells.</article-title><source>J Biol Chem</source><volume>281</volume><fpage>2740</fpage><lpage>2749</lpage><pub-id pub-id-type="pmid">16330545</pub-id></citation></ref><ref id="pone.0005354-Blumenthal1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blumenthal</surname><given-names>A</given-names></name><name><surname>Ehlers</surname><given-names>S</given-names></name><name><surname>Lauber</surname><given-names>J</given-names></name><name><surname>Buer</surname><given-names>J</given-names></name><name><surname>Lange</surname><given-names>C</given-names></name><etal/></person-group><year>2006</year><article-title>The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation.</article-title><source>Blood</source><volume>108</volume><fpage>965</fpage><lpage>973</lpage><pub-id pub-id-type="pmid">16601243</pub-id></citation></ref><ref id="pone.0005354-Pereira1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>C</given-names></name><name><surname>Schaer</surname><given-names>DJ</given-names></name><name><surname>Bachli</surname><given-names>EB</given-names></name><name><surname>Kurrer</surname><given-names>MO</given-names></name><name><surname>Schoedon</surname><given-names>G</given-names></name></person-group><year>2008</year><article-title>Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>28</volume><fpage>504</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">18174455</pub-id></citation></ref><ref id="pone.0005354-Sen1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>M</given-names></name><name><surname>Lauterbach</surname><given-names>K</given-names></name><name><surname>El-Gabalawy</surname><given-names>H</given-names></name><name><surname>Firestein</surname><given-names>GS</given-names></name><name><surname>Corr</surname><given-names>M</given-names></name><etal/></person-group><year>2000</year><article-title>Expression and function of wingless and frizzled homologs in rheumatoid arthritis.</article-title><source>Proc Natl Acad Sci U S A</source><volume>97</volume><fpage>2791</fpage><lpage>2796</lpage><pub-id pub-id-type="pmid">10688908</pub-id></citation></ref><ref id="pone.0005354-Mikels1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mikels</surname><given-names>AJ</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><year>2006</year><article-title>Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context.</article-title><source>PLoS Biol</source><volume>4</volume><fpage>e115</fpage><pub-id pub-id-type="pmid">16602827</pub-id></citation></ref><ref id="pone.0005354-Murphy1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>LL</given-names></name><name><surname>Hughes</surname><given-names>CC</given-names></name></person-group><year>2002</year><article-title>Endothelial cells stimulate T cell NFAT nuclear translocation in the presence of cyclosporin A: involvement of the wnt/glycogen synthase kinase-3 beta pathway.</article-title><source>J Immunol</source><volume>169</volume><fpage>3717</fpage><lpage>3725</lpage><pub-id pub-id-type="pmid">12244165</pub-id></citation></ref><ref id="pone.0005354-Reddy1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>ST</given-names></name><name><surname>Andl</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>MM</given-names></name><name><surname>Morrisey</surname><given-names>EE</given-names></name><name><surname>Millar</surname><given-names>SE</given-names></name></person-group><year>2004</year><article-title>Expression of Frizzled genes in developing and postnatal hair follicles.</article-title><source>J Invest Dermatol</source><volume>123</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">15245425</pub-id></citation></ref><ref id="pone.0005354-Roarty1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roarty</surname><given-names>K</given-names></name><name><surname>Serra</surname><given-names>R</given-names></name></person-group><year>2007</year><article-title>Wnt5a is required for proper mammary gland development and TGF-beta-mediated inhibition of ductal growth.</article-title><source>Development</source><volume>134</volume><fpage>3929</fpage><lpage>3939</lpage><pub-id pub-id-type="pmid">17898001</pub-id></citation></ref><ref id="pone.0005354-Downs1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Downs</surname><given-names>AM</given-names></name><name><surname>Dunnill</surname><given-names>MG</given-names></name></person-group><year>2000</year><article-title>Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C.</article-title><source>Clin Exp Dermatol</source><volume>25</volume><fpage>351</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">10971502</pub-id></citation></ref><ref id="pone.0005354-Kowalzick1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kowalzick</surname><given-names>L</given-names></name></person-group><year>1997</year><article-title>Psoriasis flare caused by recombinant interferon beta injections.</article-title><source>J Am Acad Dermatol</source><volume>36</volume><fpage>501</fpage><pub-id pub-id-type="pmid">9091499</pub-id></citation></ref><ref id="pone.0005354-Eriksen1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eriksen</surname><given-names>KW</given-names></name><name><surname>Lovato</surname><given-names>P</given-names></name><name><surname>Skov</surname><given-names>L</given-names></name><name><surname>Krejsgaard</surname><given-names>T</given-names></name><name><surname>Kaltoft</surname><given-names>K</given-names></name><etal/></person-group><year>2005</year><article-title>Increased sensitivity to interferon-alpha in psoriatic T cells.</article-title><source>J Invest Dermatol</source><volume>125</volume><fpage>936</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">16297193</pub-id></citation></ref><ref id="pone.0005354-Romanowska1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romanowska</surname><given-names>M</given-names></name><name><surname>al Yacoub</surname><given-names>N</given-names></name><name><surname>Seidel</surname><given-names>H</given-names></name><name><surname>Donandt</surname><given-names>S</given-names></name><name><surname>Gerken</surname><given-names>H</given-names></name><etal/></person-group><year>2008</year><article-title>PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor.</article-title><source>J Invest Dermatol</source><volume>128</volume><fpage>110</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">17637826</pub-id></citation></ref><ref id="pone.0005354-Hida1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hida</surname><given-names>S</given-names></name><name><surname>Ogasawara</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Takayanagi</surname><given-names>H</given-names></name><etal/></person-group><year>2000</year><article-title>CD8(&#x0002b;) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling.</article-title><source>Immunity</source><volume>13</volume><fpage>643</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">11114377</pub-id></citation></ref><ref id="pone.0005354-Reischl1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reischl</surname><given-names>J</given-names></name><name><surname>Schwenke</surname><given-names>S</given-names></name><name><surname>Beekman</surname><given-names>JM</given-names></name><name><surname>Mrowietz</surname><given-names>U</given-names></name><name><surname>Sturzebecher</surname><given-names>S</given-names></name><etal/></person-group><year>2007</year><article-title>Increased expression of Wnt5a in psoriatic plaques.</article-title><source>J Invest Dermatol</source><volume>127</volume><fpage>163</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">16858420</pub-id></citation></ref><ref id="pone.0005354-alYacoub1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>al Yacoub</surname><given-names>N</given-names></name><name><surname>Romanowska</surname><given-names>M</given-names></name><name><surname>Haritonova</surname><given-names>N</given-names></name><name><surname>Foerster</surname><given-names>J</given-names></name></person-group><year>2007</year><article-title>Optimized production and concentration of lentiviral vectors containing large inserts.</article-title><source>J Gene Med</source><volume>9</volume><fpage>579</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">17533614</pub-id></citation></ref><ref id="pone.0005354-Haider1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haider</surname><given-names>AS</given-names></name><name><surname>Peters</surname><given-names>SB</given-names></name><name><surname>Kaporis</surname><given-names>H</given-names></name><name><surname>Cardinale</surname><given-names>I</given-names></name><name><surname>Fei</surname><given-names>J</given-names></name><etal/></person-group><year>2006</year><article-title>Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia.</article-title><source>J Invest Dermatol</source><volume>126</volume><fpage>869</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">16470182</pub-id></citation></ref><ref id="pone.0005354-Guo1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>N</given-names></name><name><surname>Hawkins</surname><given-names>C</given-names></name><name><surname>Nathans</surname><given-names>J</given-names></name></person-group><year>2004</year><article-title>Frizzled6 controls hair patterning in mice.</article-title><source>Proc Natl Acad Sci U S A</source><volume>101</volume><fpage>9277</fpage><lpage>9281</lpage><pub-id pub-id-type="pmid">15169958</pub-id></citation></ref><ref id="pone.0005354-Hung1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>BS</given-names></name><name><surname>Wang</surname><given-names>XQ</given-names></name><name><surname>Cam</surname><given-names>GR</given-names></name><name><surname>Rothnagel</surname><given-names>JA</given-names></name></person-group><year>2001</year><article-title>Characterization of mouse Frizzled-3 expression in hair follicle development and identification of the human homolog in keratinocytes.</article-title><source>J Invest Dermatol</source><volume>116</volume><fpage>940</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">11407985</pub-id></citation></ref><ref id="pone.0005354-Safholm2"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Safholm</surname><given-names>A</given-names></name><name><surname>Tuomela</surname><given-names>J</given-names></name><name><surname>Rosenkvist</surname><given-names>J</given-names></name><name><surname>Dejmek</surname><given-names>J</given-names></name><name><surname>Harkonen</surname><given-names>P</given-names></name><etal/></person-group><year>2008</year><article-title>The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility.</article-title><source>Clin Cancer Res</source><volume>14</volume><fpage>6556</fpage><lpage>6563</lpage><pub-id pub-id-type="pmid">18927296</pub-id></citation></ref><ref id="pone.0005354-Cargill1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cargill</surname><given-names>M</given-names></name><name><surname>Schrodi</surname><given-names>SJ</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Garcia</surname><given-names>VE</given-names></name><name><surname>Brandon</surname><given-names>R</given-names></name><etal/></person-group><year>2007</year><article-title>A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.</article-title><source>Am J Hum Genet</source><volume>80</volume><fpage>273</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">17236132</pub-id></citation></ref><ref id="pone.0005354-Krueger1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>GG</given-names></name><name><surname>Langley</surname><given-names>RG</given-names></name><name><surname>Leonardi</surname><given-names>C</given-names></name><name><surname>Yeilding</surname><given-names>N</given-names></name><name><surname>Guzzo</surname><given-names>C</given-names></name><etal/></person-group><year>2007</year><article-title>A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.</article-title><source>N Engl J Med</source><volume>356</volume><fpage>580</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">17287478</pub-id></citation></ref><ref id="pone.0005354-Katoh1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katoh</surname><given-names>M</given-names></name><name><surname>Katoh</surname><given-names>M</given-names></name></person-group><year>2007</year><article-title>STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review).</article-title><source>Int J Mol Med</source><volume>19</volume><fpage>273</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">17203201</pub-id></citation></ref><ref id="pone.0005354-Sano1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>KS</given-names></name><name><surname>Carbajal</surname><given-names>S</given-names></name><name><surname>Clifford</surname><given-names>J</given-names></name><name><surname>Peavey</surname><given-names>M</given-names></name><etal/></person-group><year>2005</year><article-title>Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model.</article-title><source>Nat Med</source><volume>11</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">15592573</pub-id></citation></ref><ref id="pone.0005354-Fathke1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fathke</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>L</given-names></name><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>B</given-names></name><name><surname>Hocking</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>Wnt signaling induces epithelial differentiation during cutaneous wound healing.</article-title><source>BMC Cell Biol</source><volume>7</volume><fpage>4</fpage><pub-id pub-id-type="pmid">16426441</pub-id></citation></ref><ref id="pone.0005354-Sen2"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>M</given-names></name><name><surname>Chamorro</surname><given-names>M</given-names></name><name><surname>Reifert</surname><given-names>J</given-names></name><name><surname>Corr</surname><given-names>M</given-names></name><name><surname>Carson</surname><given-names>DA</given-names></name></person-group><year>2001</year><article-title>Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation.</article-title><source>Arthritis Rheum</source><volume>44</volume><fpage>772</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">11315916</pub-id></citation></ref><ref id="pone.0005354-Boyman1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boyman</surname><given-names>O</given-names></name><name><surname>Hefti</surname><given-names>HP</given-names></name><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Nickoloff</surname><given-names>BJ</given-names></name><name><surname>Suter</surname><given-names>M</given-names></name><etal/></person-group><year>2004</year><article-title>Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha.</article-title><source>J Exp Med</source><volume>199</volume><fpage>731</fpage><lpage>736</lpage><pub-id pub-id-type="pmid">14981113</pub-id></citation></ref><ref id="pone.0005354-Wolf1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>R</given-names></name><name><surname>Ruocco</surname><given-names>V</given-names></name></person-group><year>1999</year><article-title>Triggered psoriasis.</article-title><source>Adv Exp Med Biol</source><volume>455</volume><fpage>221</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">10599347</pub-id></citation></ref><ref id="pone.0005354-Hampton1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hampton</surname><given-names>PJ</given-names></name><name><surname>Ross</surname><given-names>OK</given-names></name><name><surname>Reynolds</surname><given-names>NJ</given-names></name></person-group><year>2007</year><article-title>Increased nuclear beta-catenin in suprabasal involved psoriatic epidermis.</article-title><source>Br J Dermatol</source><volume>157</volume><fpage>1168</fpage><lpage>1177</lpage><pub-id pub-id-type="pmid">17916213</pub-id></citation></ref><ref id="pone.0005354-Takada1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takada</surname><given-names>I</given-names></name><name><surname>Mihara</surname><given-names>M</given-names></name><name><surname>Suzawa</surname><given-names>M</given-names></name><name><surname>Ohtake</surname><given-names>F</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><etal/></person-group><year>2007</year><article-title>A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation.</article-title><source>Nat Cell Biol</source><volume>9</volume><fpage>1273</fpage><lpage>1285</lpage><pub-id pub-id-type="pmid">17952062</pub-id></citation></ref><ref id="pone.0005354-Wang1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LH</given-names></name><name><surname>Yang</surname><given-names>XY</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><etal/></person-group><year>2004</year><article-title>Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells.</article-title><source>Immunity</source><volume>20</volume><fpage>205</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">14975242</pub-id></citation></ref><ref id="pone.0005354-Platanias1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Platanias</surname><given-names>LC</given-names></name></person-group><year>2005</year><article-title>Mechanisms of type-I- and type-II-interferon-mediated signalling.</article-title><source>Nat Rev Immunol</source><volume>5</volume><fpage>375</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">15864272</pub-id></citation></ref><ref id="pone.0005354-Siemes1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siemes</surname><given-names>C</given-names></name><name><surname>Quast</surname><given-names>T</given-names></name><name><surname>Klein</surname><given-names>E</given-names></name><name><surname>Bieber</surname><given-names>T</given-names></name><name><surname>Hooper</surname><given-names>NM</given-names></name><etal/></person-group><year>2004</year><article-title>Normalized proliferation of normal and psoriatic keratinocytes by suppression of sAPPalpha-release.</article-title><source>J Invest Dermatol</source><volume>123</volume><fpage>556</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">15304096</pub-id></citation></ref><ref id="pone.0005354-Herzog1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herzog</surname><given-names>V</given-names></name><name><surname>Kirfel</surname><given-names>G</given-names></name><name><surname>Siemes</surname><given-names>C</given-names></name><name><surname>Schmitz</surname><given-names>A</given-names></name></person-group><year>2004</year><article-title>Biological roles of APP in the epidermis.</article-title><source>Eur J Cell Biol</source><volume>83</volume><fpage>613</fpage><lpage>624</lpage><pub-id pub-id-type="pmid">15679106</pub-id></citation></ref><ref id="pone.0005354-Ito1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Ogawa</surname><given-names>K</given-names></name><name><surname>Takeuchi</surname><given-names>K</given-names></name><name><surname>Nakada</surname><given-names>A</given-names></name><name><surname>Heishi</surname><given-names>M</given-names></name><etal/></person-group><year>2004</year><article-title>Gene expression of enzymes for tryptophan degradation pathway is upregulated in the skin lesions of patients with atopic dermatitis or psoriasis.</article-title><source>J Dermatol Sci</source><volume>36</volume><fpage>157</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">15541637</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>J.F. is supported by grants of Tenovus Scotland and Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 